ROS-induced DNA damage in the form of oxidized bases and impaired repair of SSBs has been implicated in PD etiology [
84]. Studies have reported elevated levels of 8-OHdG, resulting from DNA oxidation, in PD brains [
11,
282] and increased levels of 8-OHG in the SNpc of PD patients [
282]. Similarly, more DNA damage, indicated by elevated levels of markers γH2AX and p53-binding protein foci, is present in dopaminergic neurons of two synucleinopathy PD mouse models [
286]. Further in vitro studies with dopaminergic SH-SY5Y cell lines suggested that excessive oxidation is at least partially responsible for DDR activation observed in vivo [
286]. In comparison to age-matched controls, the SNpc of PD patients displays increased SOD levels, whereas the activities of CAT, GPx and GR are similar as controls [
287]. Reduced levels of GSH and altered GSH/GSSG ratio, resulting in more of the oxidized form, have been detected in the SNpc of PD brains [
288]. Similarly, depletion of GSH is observed in patients with a pre-symptomatic form of PD, known as incidental Lewy body disease, compared to control subjects [
289]. Under elevated oxidative stress conditions, reduction in GSH results in dopaminergic neuronal loss [
290]. In addition, depletion of GSH results in increased NO and MPTP/MPP + toxicity in dopaminergic neurons in animal models of PD [
291,
292]. Glutamyl cysteine ethyl ester and GSH ethyl ester, two precursors of GSH, increase GSH levels in neuronal cells both in vitro and in vivo and are protective against oxidative and nitrosative stress [
293,
294]. Similarly, intracellular GSH levels are also rescued by thiol antioxidants such as α-lipoic acid in both in vitro and in vivo PD models [
295,
296]. Depletion of the antioxidant vitamin C has also been detected in PD [
297] and vitamin C levels in lymphocytes may be a potential biomarker of disease progression in PD [
298]. Furthermore, cells with lower levels of uric acid (UA) are more vulnerable to oxidative damage [
299] and individuals with low cellular uric acid levels may be at a greater risk of developing PD [
300]. UA prevents 6-hydroxydopamine (6-OHDA)-induced oxidative damage in neuron-like PC12 cells and increases GSH and SOD1 [
301]. Similarly, GSH levels, SOD1 activity and dopaminergic neuronal damage are rescued in a 6-OHDA rat model of PD following UA treatment [
302]. SOD1 may be a first-line protection against enhanced ROS production in PD patients [
303]. RNS, such as NO and its metabolite PN, may also cause DNA damage in PD [
11] by reacting with superoxide anion radicals. NO can then generate more oxidatively active PN, which in turn may induce DNA fragmentation [
74].